Fever following Covid-19 vaccination in subjects with Brugada syndrome: Incidence and management.
Brugada syndrome
Covid-19
corona virus
fever
vaccination
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
08
05
2022
received:
04
02
2022
accepted:
07
06
2022
pubmed:
14
6
2022
medline:
24
8
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
Fever is a potential side effect of the Covid-19 vaccination. Patients with Brugada syndrome (BrS) have an increased risk of life-threatening arrhythmias when experiencing fever. Prompt treatment with antipyretic drugs is suggested in these patients. To evaluate the incidence and management of fever within 48 h from Covid-19 vaccination among BrS patients. One hundred sixty-three consecutive patients were enrolled in a prospective registry involving five European hospitals with a dedicated inherited disease ambulatory. The mean age was 50 ± 14 years and 121 (75%) patients were male. Prevalence of Brugada electrocardiogram (ECG) pattern type-1, -2, and -3 was 32%, 44%, and 24%, respectively. Twenty-eight (17%) patients had an implantable cardioverter-defibrillator (ICD). Fever occurred in 32 (19%) BrS patients after 16 ± 10 h from vaccination, with a peak of body temperature of 37.9° ± 0.5°. Patients with fever were younger (39 ± 13 vs. 48 ± 13 years, p = .04). No additional differences in terms of sex and cardiovascular risk factors were found between patients with fever and not. Twenty-seven (84%) out of 32 patients experienced mild fever and five (16%) moderate fever. Pharmacological treatment with antipyretic drugs was required in 18 (56%) out of 32 patients and was associated with the resolution of symptoms. No patient required hospital admission and no arrhythmic episode was recorded in patients with ICD within 48 h after vaccination. No induced type 1 BrS ECG pattern and new ECG features were found among patients with moderate fever. Fever is a common side effect in BrS patients after the Covid-19 vaccination. Careful evaluation of body temperature and prompt treatment with antipyretic drugs may be needed.
Sections du résumé
BACKGROUND
Fever is a potential side effect of the Covid-19 vaccination. Patients with Brugada syndrome (BrS) have an increased risk of life-threatening arrhythmias when experiencing fever. Prompt treatment with antipyretic drugs is suggested in these patients.
AIM OF THE STUDY
To evaluate the incidence and management of fever within 48 h from Covid-19 vaccination among BrS patients.
METHODS
One hundred sixty-three consecutive patients were enrolled in a prospective registry involving five European hospitals with a dedicated inherited disease ambulatory.
RESULTS
The mean age was 50 ± 14 years and 121 (75%) patients were male. Prevalence of Brugada electrocardiogram (ECG) pattern type-1, -2, and -3 was 32%, 44%, and 24%, respectively. Twenty-eight (17%) patients had an implantable cardioverter-defibrillator (ICD). Fever occurred in 32 (19%) BrS patients after 16 ± 10 h from vaccination, with a peak of body temperature of 37.9° ± 0.5°. Patients with fever were younger (39 ± 13 vs. 48 ± 13 years, p = .04). No additional differences in terms of sex and cardiovascular risk factors were found between patients with fever and not. Twenty-seven (84%) out of 32 patients experienced mild fever and five (16%) moderate fever. Pharmacological treatment with antipyretic drugs was required in 18 (56%) out of 32 patients and was associated with the resolution of symptoms. No patient required hospital admission and no arrhythmic episode was recorded in patients with ICD within 48 h after vaccination. No induced type 1 BrS ECG pattern and new ECG features were found among patients with moderate fever.
CONCLUSION
Fever is a common side effect in BrS patients after the Covid-19 vaccination. Careful evaluation of body temperature and prompt treatment with antipyretic drugs may be needed.
Identifiants
pubmed: 35695789
doi: 10.1111/jce.15596
pmc: PMC9350146
doi:
Substances chimiques
Antipyretics
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1874-1879Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Europace. 2019 Sep 1;21(9):1410-1421
pubmed: 31106349
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
PLoS One. 2016 Nov 9;11(11):e0166143
pubmed: 27829006
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Ann Intern Med. 2008 Aug 5;149(3):216-8
pubmed: 18678856
Heart Rhythm. 2016 Jul;13(7):1515-20
pubmed: 27033637
J Infect Public Health. 2011 Aug;4(3):108-24
pubmed: 21843857
Circ Genom Precis Med. 2018 Nov;11(11):e002263
pubmed: 30571189
Int J Mol Sci. 2018 Feb 28;19(3):
pubmed: 29495624
Ann Noninvasive Electrocardiol. 2020 May;25(3):e12723
pubmed: 31746533
J Am Coll Cardiol. 2015 Nov 3;66(18):1976-1986
pubmed: 26516000
J Cardiovasc Electrophysiol. 2022 Aug;33(8):1874-1879
pubmed: 35695789
Heart Rhythm. 2009 Sep;6(9):1335-41
pubmed: 19716089
Eur Heart J. 2021 Mar 31;42(13):1270-1272
pubmed: 33595083
Front Cell Dev Biol. 2019 Nov 01;7:261
pubmed: 31737628
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Curr Probl Cardiol. 2016 Jan;41(1):7-57
pubmed: 26671757
Heart Rhythm. 2013 Dec;10(12):1932-63
pubmed: 24011539
Circ J. 2022 Feb 25;86(3):474
pubmed: 34615807
Circulation. 2002 Nov 5;106(19):2514-9
pubmed: 12417552
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Heart Rhythm. 2018 Sep;15(9):1394-1401
pubmed: 29649615
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Heart Rhythm. 2013 Sep;10(9):1375-82
pubmed: 23872691
Eur Heart J. 2017 Oct 21;38(40):3029-3034
pubmed: 29020354